HELIUS MEDICAL TECHNOLOGIES (HSDT)
US42328V8019 - Common Stock
HSDT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 196 industry peers in the Health Care Equipment & Supplies industry. The financial health of HSDT is average, but there are quite some concerns on its profitability. HSDT is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year HSDT has reported negative net income.
HSDT had negative earnings in each of the past 5 years.
HSDT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
HSDT has a worse Return On Assets (-115.05%) than 83.67% of its industry peers.
HSDT has a Return On Equity of -376.60%. This is amonst the worse of the industry: HSDT underperforms 85.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -115.05% | ||
| ROE | -376.6% | ||
| ROIC | N/A |
ROA(3y)-108.35%
ROA(5y)-127.05%
ROE(3y)-236.75%
ROE(5y)-248.57%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Gross Margin value of 9.47%, HSDT is not doing good in the industry: 83.16% of the companies in the same industry are doing better.
HSDT's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for HSDT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 9.47% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-38.59%
GM growth 5Y-37.58%
2. Health
2.1 Basic Checks
HSDT has more shares outstanding than it did 1 year ago.
The number of shares outstanding for HSDT has been increased compared to 5 years ago.
There is no outstanding debt for HSDT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -33.02, we must say that HSDT is in the distress zone and has some risk of bankruptcy.
HSDT has a worse Altman-Z score (-33.02) than 90.31% of its industry peers.
There is no outstanding debt for HSDT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -33.02 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 3.96 indicates that HSDT has no problem at all paying its short term obligations.
With a decent Current ratio value of 3.96, HSDT is doing good in the industry, outperforming 60.71% of the companies in the same industry.
A Quick Ratio of 3.72 indicates that HSDT has no problem at all paying its short term obligations.
With a decent Quick ratio value of 3.72, HSDT is doing good in the industry, outperforming 65.31% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.96 | ||
| Quick Ratio | 3.72 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 87.53% over the past year.
HSDT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -18.17%.
Measured over the past years, HSDT shows a small growth in Revenue. The Revenue has been growing by 6.05% on average per year.
EPS 1Y (TTM)87.53%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q82.71%
Revenue 1Y (TTM)-18.17%
Revenue growth 3Y-0.81%
Revenue growth 5Y6.05%
Revenue growth Q2Q-52.48%
3.2 Future
Based on estimates for the next years, HSDT will show a very strong growth in Earnings Per Share. The EPS will grow by 29.30% on average per year.
HSDT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 213.33% yearly.
EPS Next Y25.9%
EPS Next 2Y27.09%
EPS Next 3Y29.3%
EPS Next 5YN/A
Revenue Next Year29.18%
Revenue Next 2Y158.55%
Revenue Next 3Y199.56%
Revenue Next 5Y213.33%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for HSDT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HSDT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
HSDT's earnings are expected to grow with 29.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.09%
EPS Next 3Y29.3%
5. Dividend
5.1 Amount
HSDT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
HELIUS MEDICAL TECHNOLOGIES
NASDAQ:HSDT (4/18/2024, 7:00:02 PM)
5.11
-0.07 (-1.35%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.63M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -115.05% | ||
| ROE | -376.6% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 9.47% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.96 | ||
| Quick Ratio | 3.72 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)87.53%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y25.9%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-18.17%
Revenue growth 3Y-0.81%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y